Membership Home Portfolio Stocks Bonds Funds ETFs CEFs Markets Tools Real Life Finance Discuss
Home>Topics>>Incyte Pharmaceuticals Is Primed For A Run

Incyte Pharmaceuticals Is Primed For A Run

Healthcare Sector and Stocks Analysis from Seeking Alpha

Tue, 5 Feb 2013

By Alpha Cardinal : By Paul Jaschke, Ph.D., Ju Lu Ph.D., Widya Mulyasasmita and Luke J. Lee Incyte Pharmaceuticals ( INCY ) is focused on discovering, developing, and commercializing novel small molecule drugs for serious, unmet oncology and inflammatory diseases and needs. They won approval for ...

Read the rest of this article on Healthcare Sector and Stocks Analysis from Seeking Alpha

Related Videos

  1. Behind the Bullish Take on Our Top Pharma Pick

    Thu, 21 Jan 2010

    A large generics business and niche pipeline keep Novartis ahead of the curve.

  2. An Opportunistic Pharma Pick

    Tue, 7 Dec 2010

    Premature disappointment over the prospect of Vanda's sole drug has left investors with a compelling opportunity says Morningstar Opportunistic Investor's Stephen Ellis.

Content Partners
Site Directory Site Map Our Products
Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News
International Sites: Australia Canada China France Germany Hong Kong Italy The Netherlands Norway Spain U.K. Switzerland India Finland
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.